Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $375.5 million.

  • Mirum Pharmaceuticals' Cash & Current Investments rose 32.03% to $375.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 7.47%. This contributed to the annual value of $280.3 million for FY2024, which is 2.10% down from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Cash & Current Investments stood at $375.5 million, which was up 23.31% from $304.6 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash & Current Investments peaked at $434.9 million during Q3 2022, and registered a low of $132.1 million during Q1 2023.
  • In the last 3 years, Mirum Pharmaceuticals' Cash & Current Investments had a median value of $286.3 million in 2023 and averaged $287.1 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Cash & Current Investments crashed by 60.40% in 2023, and later soared by 129.30% in 2024.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Cash & Current Investments stood at $256.5 million in 2021, then dropped by 1.88% to $251.7 million in 2022, then climbed by 13.75% to $286.3 million in 2023, then dropped by 2.10% to $280.3 million in 2024, then skyrocketed by 32.03% to $375.5 million in 2025.
  • Its last three reported values are $375.5 million in Q3 2025, $304.6 million for Q2 2025, and $277.7 million during Q1 2025.